» Articles » PMID: 26246314

Reducing Ventilator-associated Pneumonia in Neonatal Intensive Care Unit Using "VAP Prevention Bundle": a Cohort Study

Abstract

Background: Ventilator-associated pneumonia (VAP) is a serious health care-associated infection, resulting in high morbidity and mortality. It also prolongs hospital stay and drives up hospital costs. Measures employed in preventing ventilator-associated pneumonia in developing countries are rarely reported. In this study we tried to assess the efficacy of our designed "VAP prevention bundle" in reducing VAP rate in our neonatal intensive care unit (NICU).

Method: This prospective before-and-after study was conducted at university hospital NICU, all neonates who had mechanical ventilation for ≥ 48 h were eligible. VAP rates were evaluated before (phase-I) and after (phase-II) full implementation of comprehensive preventive measures specifically designed by our infection control team.

Results: Of 143 mechanically ventilated neonates, 73 patients developed VAP (51%) throughout the study period (2500 mechanical ventilation days). The rate of VAP was significantly reduced from 67.8% (42/62) corresponding to 36.4 VAP episodes/1000 mechanical ventilation days (MV days) in phase-I to 38.2% (31/81) corresponding to 23 VAP/1000 MV days (RR 0.565, 95% confidence interval 0.408-0.782, p = 0.0006) after VAP prevention bundle implementation (phase-II). Parallel significant reduction in MV days/case were documented in post-intervention period (21.50 ± 7.6 days in phase-I versus 10.36 ± 5.2 days in phase-II, p = 0.000). There were a trend toward reduction in NICU length of stay (23.9 ± 10.3 versus 22.8 ± 9.6 days, p = 0.56) and overall mortality (25% versus 17.3%, p = 0.215) between the two phases but didn't reach statistical significance. The commonest micro-organisms isolated throughout the study were gram-negative bacteria (63/66, 95.5%) particularly Klebsilla pneumonia (55/66, 83.4%).

Conclusion: Implementation of multifaceted infection control bundle resulted in reduction of VAP rate, length of stay in our NICU.

Citing Articles

Effect of taurine supplementation on preventing ventilator-associated pneumonia in pediatrics under mechanical ventilation, a randomized controlled double-blind clinical trial.

Shirzad-Yazdi N, Shorafa E, Abootalebi S, Heidari R, Hojabri K, Doostfatemeh M Front Pediatr. 2025; 12:1490247.

PMID: 39867697 PMC: 11757258. DOI: 10.3389/fped.2024.1490247.


Ethical considerations regarding the treatment of extremely preterm infants at the limit of viability: a comprehensive review.

Arimitsu T, Hatayama K, Gaughwin K, Kusuda S Eur J Pediatr. 2025; 184(2):140.

PMID: 39814940 DOI: 10.1007/s00431-025-05976-2.


Prevention and Treatment of Neonatal Infections in Facility and Community Settings of Low- and Middle-Income Countries: A Descriptive Review.

Lee Him R, Rehman S, Sihota D, Yasin R, Azhar M, Masroor T Neonatology. 2024; 122(Suppl 1):173-208.

PMID: 39532080 PMC: 11875423. DOI: 10.1159/000541871.


The spectrum of pneumonia among intubated neonates in the neonatal intensive care unit.

Bondarev D, Ryan R, Mukherjee D J Perinatol. 2024; 44(9):1235-1243.

PMID: 38698211 PMC: 11379627. DOI: 10.1038/s41372-024-01973-9.


The Status and Influencing Factors of COVID-19 Vaccination for 3-7-Year-Old Children Born Prematurely.

Shi J, Zhao F, Yang W, Zhu Y, Wang M, Yi B Patient Prefer Adherence. 2024; 18:787-796.

PMID: 38572223 PMC: 10987788. DOI: 10.2147/PPA.S451654.


References
1.
Koksal N, Hacimustafaoglul M, Celebi S, Ozakin C . Nonbronchoscopic bronchoalveolar lavage for diagnosing ventilator-associated pneumonia in newborns. Turk J Pediatr. 2006; 48(3):213-20. View

2.
Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A, Olsen M, Fraser V . Ventilator-associated pneumonia in extremely preterm neonates in a neonatal intensive care unit: characteristics, risk factors, and outcomes. Pediatrics. 2003; 112(6 Pt 1):1283-9. DOI: 10.1542/peds.112.6.1283. View

3.
Craven D, Goularte T, Make B . Contaminated condensate in mechanical ventilator circuits. A risk factor for nosocomial pneumonia?. Am Rev Respir Dis. 1984; 129(4):625-8. View

4.
Omrane R, Eid J, Perreault M, Yazbeck H, Berbiche D, Gursahaney A . Impact of a protocol for prevention of ventilator-associated pneumonia. Ann Pharmacother. 2007; 41(9):1390-6. DOI: 10.1345/aph.1H678. View

5.
. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171(4):388-416. DOI: 10.1164/rccm.200405-644ST. View